alveogene https://validator.w3.org/feed/docs/rss2.html Update on 2025 Development Progress ATS 2025 Keynote Shares Exciting Progress in Gene Therapies Using AlveoGene’s InGenuiTy® Platform in Cystic Fibrosis – and beyond! AlveoGene Provides Latest Company Update JPM Week 2026 and RESI San Francisco Product Pipeline Technology Platform About Us Presentation block 1 New Paper Confirms Safety of InGenuiTy®️ Vector Delivered Directly to the Lungs AlveoGene’s Novel, Inhaled Gene Therapy AVG-002 Receives Orphan Drug Designation from FDA for Lethal Neonatal Surfactant Protein B (SP-B) Deficiency AlveoGene on Biotech TV AlveoGene Receives Rare Pediatric Disease Designation (RPDD) from FDA for AVG-002, its Novel, Inhaled Gene Therapy for Lethal Neonatal Surfactant Protein B (SP-B) Deficiency News CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Correction of a chronic pulmonary disease through lentiviral vector-mediated protein expression. Lung-targeting lentiviral vector for passive immunisation against influenza. Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy. Contact Dr Gerry McLachlan Dr Christopher Boyd Professor Stephen Hyde Professor Deborah Gill Professor Uta Griesenbach NACFC 2022 | S01: Design of Clinical Trials to Evaluate Nucleotide-Based Interventions – YouTube Professor Eric Alton David Hipkiss AlveoGene Launches to Develop Unique Inhaled Gene Therapies for Rare Respiratory Disorders Popup layout Team post layout Home